Identi Healthcare: Is the U.S. Funnel Deep Enough to Change the Numbers?
Identi now has more than a marketing promise in the U.S.: OrthoVirginia and Mayo Clinic outline a staged commercial funnel with orders, pilots, and possible expansion. But the 2025 report also makes clear that the gap between opening doors and moving reported numbers is still open.
The U.S. funnel now looks commercial, but it still has not hit the income statement
The main article argued that Identi's margin improvement still falls short of broad commercial proof. This follow-up isolates the U.S. track, because that is where the story is now deeper than a list of meetings, presentations, or isolated pilots. There is an ambulatory network with a concrete order, a more advanced relationship with Mayo Clinic, and management language that frames 2026 as a year of execution, monetization, and U.S. operating build-out.
The core point is simple: the U.S. funnel is now deep enough to deserve a serious commercial read, but it is still not deep enough to count as a proven change in the reported numbers. What is missing is not another recognizable name. What is missing is the clean move from initial order and pilot to wider deployment, revenue recognition, and a recurring service layer.
The 2025 top line makes that gap very clear. The U.S. contributed only NIS 510 thousand, about 5% of revenue, barely changed from NIS 486 thousand in 2024. At the same time, product sales fell to NIS 3.314 million from NIS 4.212 million, and the company explains that some of the major framework agreements, led by the strategic Mayo Clinic engagement, were completed only after the balance-sheet date, during the first quarter of 2026. In other words, the U.S. is already producing commercial evidence, but the 2025 report still captures the story just before that evidence reaches reported revenue.
What matters is that the company is already describing the U.S. as its core target market, not as a testing ground. It says it operates there through both direct sales and partners, explicitly names major networks and medical centers, and describes a staged international model that begins with a pilot or initial order and only then expands across a broader network. That is commercialization language. It is just not scale language yet.
What has already been proven, and what is still contingent
To read Mayo Clinic and OrthoVirginia correctly, it helps to start with the company's own description of its international model: a pilot or initial order to prove capability, followed by broader deployment across operating rooms, procedure rooms, or supply areas. That means these are not just two more customer names. They represent two different points inside the same funnel.
| Funnel node | What is already locked in | What it means | What is still open |
|---|---|---|---|
| OrthoVirginia | In January 2026 the company received an order of about $300 thousand for Wireless PAR Weighing Bin systems for three hospitals in the network | This is a real commercial order, not a conceptual pilot. The company also describes it as part of a multi-stage network automation program | The possible expansion into Snap & Go across 25 operating rooms in the network remains company guidance, not a completed step |
| Mayo Clinic | After successfully completing the second stage of the engagement, the company received an initial order on February 1, 2026 worth about $400 thousand for 14 supply rooms | This sits further down the funnel. It is not just a commercial relationship, but a relationship that has already passed another proof point | The broader rollout is still conditional: an additional Snap & Go pilot in up to five operating rooms during Q2 2026, with wider expansion only if it succeeds |
| Sales and implementation layer | The company describes U.S. direct sales, partner channels, and two local employees as of the report date | There is now a real U.S. commercial skeleton, and the company is already in front of large organizations | That layer is still thin. Management says it will adjust staffing in the U.S. subsidiary only as large-customer sales progress |
The critical difference between Mayo and OrthoVirginia is maturity. OrthoVirginia shows that Identi can secure a first real order from a U.S. network for an AI-based weighing product. Mayo Clinic already sits one step deeper, because the company explicitly says the second stage was completed successfully before the initial order for 14 supply rooms was received. Put differently, OrthoVirginia proves access. Mayo starts testing whether that access can remain open and widen.
There is also an important cross-sell signal here. OrthoVirginia started with the weighing system, but the company already frames the next step through Snap & Go. Mayo Clinic is working on one solution while separately testing another. That matters because Identi's economics do not rely only on shipping a single hardware unit. The model depends on deeper penetration into hospital workflows.
Where the real bottleneck sits
The reason the funnel still has not "changed the numbers" is not a lack of commercial opportunities. It is the gap between commercial penetration and accounting recognition at scale.
The company says that in Israel and abroad it supplies products immediately, so it does not accumulate a meaningful order backlog. That is more important than it may first appear. When there is no meaningful reported backlog, there is less bridge between a commercial story and the income statement. Even if an interesting agreement is signed or an initial order is received, the next report will still depend mostly on the pace of deployment, delivery, and actual recognition, not on the existence of a pipeline by itself.
The revenue model reinforces that reading. In the first year of a customer relationship, the company records both product revenue and monthly system-service fees. From the second year onward, the customer pays only for the system services. So a real change in the numbers requires both stages together: first, enough physical deployment to create initial revenue; then, a broad enough installed base to build a recurring service layer. Without the first stage, the second one cannot form.
That brings the real bottleneck into focus: the U.S. operating layer is still narrow relative to the ambition. As of the report date, the company had only two employees in the United States, alongside intensive involvement by the CEO and the sales team from Israel. At the same time, management says that as sales to large U.S. customers progress in 2026, it will adjust staffing in the U.S. subsidiary for project management, user training, and ongoing support. In plain terms, the company itself is saying that the next stage of the funnel requires an implementation layer that still has to be built.
That point becomes even sharper when looking at the U.S. subsidiary. It was formed specifically to contract with U.S. customers, yet as of the report date the company had still not executed U.S. engagements through that subsidiary, even though it aims to do so as the customer base grows. It is a small disclosure, but an analytically important one: U.S. commercial access is opening, while the local operating structure is still not fully institutionalized.
There is one more operating warning flag here. The company's activity is still centered mainly in Israel, and during the late-February 2026 emergency period it already disclosed some slowdown in implementations at Israeli hospitals and specific logistics difficulties in supplying systems to customers abroad, including in the U.S. That does not break the U.S. thesis, but it does remind readers that U.S. growth still depends on an execution base concentrated in Israel.
What would need to happen for the funnel to change the numbers
Management frames the coming year quite clearly: execute signed agreements and transactions, expand the U.S. sales base, and adjust manpower as large-customer sales advance. That is the language of a proof year, not a storytelling year.
First checkpoint: Mayo Clinic needs to move from the initial order and the additional Snap & Go pilot to wider deployment inside the network. If the five-operating-room pilot succeeds and leads to broader implementation, that would already mark a shift from controlled validation to something much more economic.
Second checkpoint: OrthoVirginia needs to prove that a three-hospital order is a template, not an event. If the activity remains a single-product order, its strategic value is limited. If it broadens inside the network and also crosses into Snap & Go, the read changes materially.
Third checkpoint: the local operating layer needs to carry more of the weight. As long as the sales effort is still run mainly from Israel and the U.S. execution layer is only being assembled, it is hard to call this a stable engine. The shift toward a model where the U.S. subsidiary and local staff carry more project management, implementation, and support will matter as much as the orders themselves.
Fourth checkpoint: the U.S. line needs to move in the financials. 2025 ended with only NIS 510 thousand from the U.S. Without a visible step-up in the next reports, even a string of strong customer names will not be enough.
The key point is that the funnel already exists. The company is not starting from zero in the U.S. But the funnel is still built around several proof points, not around a repeatable engine. That is why the answer to the title question is intentionally two-sided: yes, the funnel is already deep enough to justify serious attention. No, it is still not deep enough to say the numbers have already changed.
Conclusion
Identi's U.S. story has clearly moved forward. It no longer rests only on vision, conferences, or marketing language. OrthoVirginia and Mayo Clinic show access to large healthcare organizations, a staged deployment model, and multiple products that can be sold into the same account over time. That is exactly what small companies usually lack when they tell a U.S. commercialization story.
But discipline still matters here. The 2025 report does not yet show that the U.S. has changed the company's economics. It shows that the U.S. is getting closer to the point where it might. Until that is visible in broader deployments, recognized revenue, and a thicker local execution layer, this remains a promising funnel, not a proven engine.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.